Can a once-daily pill ease stuttering? a trial puts lumateperone to the test.
NCT ID NCT07734103
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the drug lumateperone can reduce stuttering symptoms in adults with moderate to severe childhood-onset stuttering. Participants take either lumateperone (21 mg or 42 mg) or a placebo daily for several weeks. Researchers will measure changes in stuttering severity using self-report scales and clinician assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drug called lumateperone (ITI-007) taken as a tablet once daily
- What this could lead to
- If effective, lumateperone could become a new medication option to help reduce stuttering symptoms in adults.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply widely. The drug may cause side effects or prove no better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STUTTERING, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CSTrials
RECRUITINGCosta Mesa, California, 92662, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scans and speech tasks aim to unlock the secrets of stuttering
- Can an app help people who stutter speak more fluently?
- Brain zaps show promise for stuttering relief
- Brain zaps for stuttering? tiny trial tests rTMS
- Brain scans reveal how stuttering works in new drug study
- Brain zaps may unlock fluency for people who stutter